Zofenopril (calcium)

• UNSPSC Description:

  Zofenopril Calcium (SQ26991) is an orally active angiotensin-converting enzyme (ACE) inhibitor with antioxidant activity and cardioprotective effects. Zofenopril Calcium reduces ROS production and GSH consumption and helps inhibit foam cell formation, thus slowing the progression of atherosclerosis. Zofenopril Calcium prevents cardiac damage caused by chronic Doxorubicin (HY-15142A)[1][2].

• Target Antigen:

  Angiotensin-converting Enzyme (ACE); Reactive Oxygen Species

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Zofenopril-calcium.html

• Purity:

  99.76

• Solubility:

  DMSO : 2 mg/mL (ultrasonic)

• Smiles:

  O=C(N(C[C@@H](SC1=CC=CC=C1)C2)[C@@H]2C([O-])=O)[C@H](C)CSC(C3=CC=CC=C3)=O.[0.5Ca2+]

• Molecular Weight:

  448.58

• References & Citations:

  [1]Cominacini L, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens. 2002 Oct;15(10 Pt 1):891-5.|[2]Sacco G, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001 Feb 23;414(1):71-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  81938-43-4